RE:RE:RE:RE:RE:AA ?And on that point of post-approval activity ... such approval would result from the granting of accelerated approval in multiple Phase I/II Goblet-1 indications including advanced or metastatic pancreatic and SCCA (anal) cancers. Either ONCY or more likely Big Pharma can then conduct a Phase 3 confirmatory clinical trial in te aforementioned cancers, while moving pelareorep towards metastatic breast cancer & CRC towards marketing approval with or without an ADC, as outlined beforeand.